Using RNA sequencing and protein measurements of both tumor and host, we initially hypothesized that treatment with RG7356 not only affects the CD44-dependent tumor biology [23], but also modulates the malignant microenvironment by up-regulating cytokines and chemo-attractants responsible for the activation and recruitment, respectively, of tumor-associated macrophages (TAMs). This evidence concerns the gene CD44 and neoplasm.